AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) A pharmaceutical preparation for inhibiting herpes simplex virus type-1 (HSV-1) infection in a mammal comprising a substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues, wherein said substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a heparin sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor so as to produce a substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues.

2. (Currently Amended) The pharmaceutical preparation of claim 1, wherein said polysaccharide preparation is enriched for GlcN3S6S.

3. Cancelled.

4. Cancelled.

5. Cancelled.

6. Cancelled.

7. Cancelled.

8. Cancelled.

9. Cancelled.

10. Cancelled.

11. (Currently Amended) The pharmaceutical preparation of claim [[10]] 1, wherein [[the]]said 3-OST-3 enzyme is selected from the group consisteing of 3-OST-3A and 3-OST-3B.

12. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the disaccharide sequence –IdoA2S-GlcN3S6S.

13. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the trisaccharide sequence GlcNS–IdoA2S-$GlcNH_23S6S$.

14. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the tetrasaccharide sequence UA2S-GlcNS–IdoA2S-$GlcNH_23S6S$.

15. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the pentasaccharide sequence GlcNS6S-UA2S-GlcNS–IdoA2S-$GlcNH_23S6S$.

16. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the hexasaccharide sequence UA-GlcNS6S-UA2S-GlcNS–IdoA2S-$GlcNH_23S6S$.

17. Cancelled.

18. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the heptasaccharide sequence GlcNAc-UA-GlcNS6S-UA2S-GlcNS–IdoA2S-$GlcNH_23S6S$.

19. (Previously Amended) The pharmaceutical preparation of claim 1, wherein the preparation comprises the octasaccharide sequence UA-GlcNAc-UA-GlcNS6S-UA2S-GlcNS–IdoA2S-$GlcNH_23S6S$

20. (Previously Amended) The pharmaceutical preparation of claim 1, wherein said pharmaceutical preparation comprises pharmaceutically acceptable carriers selected from the group consisting of lotions, creas, jellies, liniments, ointments, alves, oils, foams, gels, washes, suppositories, slow-releasing polymers, and coatings.

21. (Previously Amended) The pharmaceutical preparation of claim 1, wherein said pharmaceutical preparation further comprises at least one skin penetrating enhancer.

22. (Previously Amended) The pharmaceutical preparation of claim 21, wherein said skin penetrating enhancer is selected from the group consisting of dimethylsulfoxide (DMSO), propylene glycol, isopropanol, ethanol, oleic acid, and N-methylpyrrolidone.

23. (Currently Amended) A method of inhibiting herpes simplex virus type- I (HSV- 1) viral infection in mammal comprising administering to a mammal at risk of HSV- I infection a therapeutically effective amount of ~~any one of the~~a pharmaceutical ~~preparations of claim 1~~ composition comprising a substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues, wherein said substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a heparin sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor.

24. (Currently Amended) A method of inhibiting herpes simplex virus type- I (HSV- 1) viral infection in mammal comprising administering to a mammal diagnosed with HSV- I infection a therapeutically effective amount of ~~any one of the~~a pharmaceutical ~~preparations of claim 1~~ composition comprising a substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues, wherein said substantially pure heparin sulfate polysaccharide preparation enriched for 3-O-sulfated glucosamine residues is obtained by the process comprising the step of contacting a heparin sulfate polysaccharide with a 3-OST-3 enzyme and a sulfate donor.

25. (New) The method of claim 23 or 24, wherein said polysaccharide preparation is enriched for structures capable of specific binding with HSV-1 gD viral glycoprotein.

26. (New) The method of claim 23 or 24, wherein said 3-OST-3 enzyme is selected from the group consisting of 3-OST-3A and 3-OST-3B.

27. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the disaccharide sequence -IdoA2S-GIcN3S6S.

28. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the trisaccharide sequence GIcNS-IdoA2S-GIcNH23S6S.

29. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the tetrasaccharide sequence UA2S-GIcNS-IdoA2S

30. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the pentasaccharide sequence GIcNS6S-UA2S-GIcNS-IdoA2S-GIcNH23S6S.

31. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the hexasaccharide sequence UA-GIcNS6S-UA2S-GIcNS-IdoA2S-GIcNH23S6S.

32. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the hexasaccharide sequence UA-GIcNS6S-UA2S-GIcNS-IdoA2S-GIcNH23S6S.

33. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the heptasaccharide sequence GIcNAc-UA-GIcNS6S-UA2S-GIcNS-IdoA2S-GIcNH23S6S.

34. (New) The method of claim 23 or 24, wherein said polysaccharide preparation comprises the octasaccharide sequence UA-GIcNAc-UA-GIcNS6S-UA2S-GIcNS-IdoA2SGlcNH23S6S.

35. (New) The method of claim 23 or 24, wherein said pharmaceutical preparation comprises pharmaceutically acceptable carrier selected from the group consisting of lotions, creams, jellies, liniments, ointments, salves, oils, foams, gels, washes, suppositories, slow-releasing polymers, and coatings.

36. (New) The method of claim 23 or 24, wherein said wherein said pharmaceutical preparation further comprises at least one skin penetrating enhancer.

37. (New) The method of claim 23 or 24, wherein said skin penetrating enhancer is selected from the group consisting of dimethylsulfoxide (DMSO), propylene glycol, isopropanol, ethanol, oleic acid, and N-methylpyrrolidone.